MedTrace Logo

Ibrutinib

Drug

Also known as: Ibtrozi, Imbruvica

Drug Profile

Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor marketed as Imbruvica. It is used for B-cell malignancies such as chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenström macroglobulinemia, and also for chronic graft-versus-host disease. The FDA first approved it on November 13, 2013.

Drug Class
Bruton's tyrosine kinase (BTK) inhibitor
Approval Status
FDA approved; first approved November 13, 2013.
Mechanism of Action
Bruton's tyrosine kinase (BTK) inhibition.
Brand Names
  • Imbruvica
Indications
  • \Chronic lymphocytic leukemia/small lymphocytic lymphoma\
  • \Waldenström macroglobulinemia\
  • \Chronic graft-versus-host disease\

Related News

Chinese Biotech Exports Surge to $137.7B as U.S. Drugmakers Rush to Acquire Chinese Candidates

China's biotech overseas technology transfer agreements reached $137.7 billion in 2025, nearly ten times the 2021 figure, as global drugmakers rush to acquire Chinese candidates. BeiGene's Brukinsa surpassed $4 billion in global sales, while Pfizer agreed to a deal with Innovent Biologics worth up to $10.5 billion. U.S. lawmakers are raising security concerns about growing dependence on Chinese biotech.

Major Trials Redefine Treatment Standards for Mantle Cell Lymphoma

Long-term results from the phase III TRIANGLE trial show ibrutinib-based regimens improve survival in younger mantle cell lymphoma patients, while the ECHO trial establishes a new standard for older patients. Advances in CAR T-cell and bispecific antibody therapies are reshaping treatment for this rare blood cancer. The findings were presented at the annual MCL Consortium meeting.

Johnson & Johnson raises forecast after earnings beat on drug growth

Johnson & Johnson raised its full-year forecast after stronger-than-expected quarterly results driven by cancer, immunology and neuroscience drugs. Sales were $24.56 billion and adjusted earnings were $2.46 per share, with Innovative Medicines sales rising 10.0% to $15.76 billion.

New Zealand Proposes Expanded Access to Cancer Treatments

Pharmac has proposed expanding access to melanoma treatments and funding two new therapies for chronic lymphocytic leukaemia. Medical researchers also highlight that New Zealanders lack access to CAR T-cell therapy domestically.

Related Clinical Trials

NCT ID Title Status Phase
NCT07377578

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

 RECRUITING PHASE3
NCT07169565

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

 NOT_YET_RECRUITING PHASE1
NCT07082868

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

 RECRUITING PHASE1
NCT07052695

Mosunetuzumab for CLL MRD Clearance

 RECRUITING PHASE1/PHASE2
NCT06649812

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

 RECRUITING PHASE2
NCT06536049

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

 RECRUITING PHASE1/PHASE2
NCT06482684

CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

 RECRUITING PHASE2
NCT06357676

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

 RECRUITING PHASE1/PHASE2
NCT06299540

Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

 RECRUITING
NCT06271616

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

 TERMINATED PHASE2